BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32184268)

  • 1. Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma.
    AlHilli M; Amarnath S; Elson P; Rybicki L; Dowdy S
    Int J Gynecol Cancer; 2020 Jun; 30(6):789-796. PubMed ID: 32184268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
    Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
    Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overuse of external beam radiotherapy for stage I endometrial cancer.
    Wright JD; Margolis B; Hou JY; Burke WM; Tergas AI; Huang Y; Hu JC; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2016 Jul; 215(1):75.e1-7. PubMed ID: 26875941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
    Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
    Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort.
    Wong AT; Rineer J; Schwartz D; Weiner J; Safdieh J; Choi K; Schreiber D
    Gynecol Oncol; 2017 Jan; 144(1):113-118. PubMed ID: 27823769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
    Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
    Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
    Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.
    Lee JK; Ghanem AI; Modh A; Burmeister C; Mahmoud O; Maxwell GL; Elshaikh MA
    Brachytherapy; 2018; 17(2):319-325. PubMed ID: 29174935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
    van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
    Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation therapy improves disease-specific survival in women with Stage II endometrioid endometrial cancer-Brachytherapy may be sufficient.
    Nwachukwu CR; Von-Eyben R; Kidd EA
    Brachytherapy; 2018; 17(2):383-391. PubMed ID: 29198879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma.
    Xiang M; Kidd EA
    J Gynecol Oncol; 2020 Jul; 31(4):e39. PubMed ID: 31912686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel low dose fractionation regimen for adjuvant vaginal brachytherapy in early stage endometrioid endometrial cancer.
    Townamchai K; Lee L; Viswanathan AN
    Gynecol Oncol; 2012 Nov; 127(2):351-5. PubMed ID: 22850411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of recurrence in early-stage endometrial carcinoma after delays in adjuvant radiation treatment.
    Zhu S; Khalil R; Altairy O; Burmeister C; Dimitrova I; Elshaikh M
    Int J Gynecol Cancer; 2021 Jan; 31(1):73-77. PubMed ID: 33087415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study.
    Rydzewski NR; Strohl AE; Donnelly ED; Kanis MJ; Lurain JR; Nieves-Neira W; Strauss JB
    Cancer; 2016 Dec; 122(23):3724-3731. PubMed ID: 27509082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Predictive of Receiving Adjuvant Radiotherapy in High-Intermediate-Risk Stage I Endometrial Cancer.
    McGunigal M; Pollock A; Doucette JT; Liu J; Chadha M; Kalir T; Gupta V
    Int J Gynecol Cancer; 2018 Jun; 28(5):882-889. PubMed ID: 29538253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of combined adjuvant chemotherapy and radiation on survival for stage III uterine cancer: is less radiation equal to more?
    Wang CJ; Christie A; Folkert MR; Xie XJ; Albuquerque K
    J Gynecol Oncol; 2018 Jul; 29(4):e49. PubMed ID: 29770620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer.
    Alektiar KM; McKee A; Venkatraman E; McKee B; Zelefsky MJ; Mychalczak BR; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):707-13. PubMed ID: 12062616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
    Xiang M; English DP; Kidd EA
    Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.